Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care

Medical Journal of Australia

Volumn 190, Issue 4 SUPPL., 2009, Pages

  Lambert, Tim J R ^a   Newcomer, John W ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEUROLEPTIC AGENT;

ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR DISEASE; COMORBIDITY; HEALTH CARE MANAGEMENT; HEALTH CARE POLICY; HUMAN; INTEGRATED HEALTH CARE SYSTEM; METABOLIC DISORDER; MORTALITY; OBESITY; PATIENT MONITORING; PRACTICE GUIDELINE; PRIMARY PREVENTION; PSYCHOSIS; SCHIZOPHRENIA; SCREENING TEST;

EID: 61849084055     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2009.tb02374.x     Document Type: Article

References (37)

1. Hennekens CH. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. J Clin Psychiatry 2007; 68 Suppl 4: 4-7.
2. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150: 1115-1121.
3. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007; 68 Suppl 4: 8-13.
4. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997; 171: 502-508.
5. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007; 64: 1123-1131.
6. Bobes J, Arango C, Aranda P, et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 2007; 90:162-173.
7. Cohn T, Prud'homme D, Streiner D, et al. Characterising coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004; 49: 753-761.
8. Holt RIG, Peveler RC. Association between antipsychotic drugs and diabetes. Diabetes Obes Metab 2006; 8:125-135.
9. Baskar V, Kamalakannan D, Holland MR, Singh BM. Does ethnic origin have an independent impact on hypertension and diabetic complications? Diabetes Obes Metab 2006; 8: 214-219.
10. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13 Suppl 1: 1-68.
11. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007; 68 Suppl 1: 20-27.
12. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 2006; 51: 492-501.
13. Morrato EH, Newcomer JW, Allen RR, Valuck RJ. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J Clin Psychiatry 2008; 69: 316-322.
14. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006; 86: 15-22.
15. Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA 2007; 298: 1794-1796.
16. Phelan M, Stradins L, Morrison S. Physical health of people with severe mental illness. BMJ 2001; 322: 443-444.
17. Lambert TJR, Chapman L, Group CW. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004; 181: 544-548.
18. Buckley PF, Miller DD, Singer B, et al. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 2005; 79: 281-288.
19. Newcomer JW, Nasrallah HA, Loebel AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 2004; 24: S1-S6.
20. Barnes TR, Paton C, Cavanagh MR, et al. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull 2007; 33: 1397-1403.
21. Haupt DW, Fahnestock PA, Flavin KA, et al. Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients. Neuropsychopharmacology 2007; 32: 2561-2569.
22. Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640-1649.
23. Jennex A, Gardner DM. Monitoring and management of metabolic risk factors in outpatients taking antipsychotic drugs: a controlled study. Can J Psychiatry 2008; 53: 34-42.
24. Sernyak MJ. Implementation of monitoring and management guidelines for second-generation antipsychotics. J Clin Psychiatry 2007; 68 Suppl 4: 14-18.
25. Goldman LS. Medical illness in patients with schizophrenia. J Clin Psychiatry 1999; 60: 10-15.
26. Druss BG, Bradford WD, Rosenheck RA, et al. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry 2001; 58: 565-572.
27. Anath J. Physical illness and psychiatric disorders. Compr Psychiatry 1984; 25: 586-593.
28. Roick C, Fritz-Wieacker A, Matschinger H, et al. Health habits of patients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2007; 42: 268-276.
29. Jeste DV, Gladsjo JA, Lindamer LA, Lacro JP. Medical comorbidity in schizophrenia. Schizophr Bull 1996; 22: 413-430.
30. Horvitz-Lennon M, Kilbourne AM, Pincus HA. From silos to bridges: meeting the general health care needs of adults with severe mental illnesses. Health Aff (Millwood) 2006; 25: 659-669.
31. Lambert TJR, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. Med J Aust 2003; 178 (9 Suppl): S67-S70.
32. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177: 212-217.
33. Kim MM, Swanson JW, Swartz MS, et al. Healthcare barriers among severely mentally ill homeless adults: evidence from the five-site health and risk study. Adm Policy Ment Health 2007; 34: 363-375.
34. Druss BG. Improving medical care for persons with serious mental illness: challenges and solutions. J Clin Psychiatry 2007; 68 Suppl 4: 40-44.
35. Lai DW, Chau SB. Effects of service barriers on health status of older Chinese immigrants in Canada. Soc Work 2007; 52: 261-269.
36. Druss BG, von Esenwein SA. improving general medical care for persons with mental and addictive disorders: systematic review. Gen Hosp Psychiatry 2006; 28: 145-153.
37. Lambert BL, Cunningham FE, Miller DR, et al. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. Am J Epidemiol 2006; 164: 672-681.